Apixaban versus Enoxaparin for Thromboprophylaxis after Hip Replacement
The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
BACKGROUND: There are various regimens for thromboprophylaxis after hip replacement. Low-molecular-weight heparins such as enoxaparin predominantly inhibit factor Xa but also inhibit thrombin to some degree. Orally active, specific factor Xa inhibitors such as apixaban may provide effective thromboprophylaxis with a lower risk of bleeding and improved ease of use. METHODS: In this double-blind, double-dummy study, we randomly assigned 5407 patients undergoing total hip replacement to receive apixaban at a dose of 2.5 mg orally twice daily or enoxaparin at a dose of 40 mg subcutaneously every 24 hours. Apixaban therapy was initiated 12 to 24 hours after closure of the surgical wound; enoxaparin therapy was initiated 12 hours before surgery. Prophylaxis was continued for 35 days after surgery, followed by bilateral venographic studies. The primary efficacy outcome was the composite of asymptomatic or symptomatic deep-vein thrombosis, nonfatal pulmonary embolism, or death from any cause during the treatment period. Patients were followed for an additional 60 days after the last intended dose of study medication. RESULTS: A total of 1949 patients in the apixaban group (72.0%) and 1917 patients in the enoxaparin group (71.0%) could be evaluated for the primary efficacy analysis. The primary efficacy outcome occurred in 27 patients in the apixaban group (1.4%) and in 74 patients in the enoxaparin group (3.9%) (relative risk with apixaban, 0.36; 95% confidence interval [CI], 0.22 to 0.54; P<0.001 for both noninferiority and superiority; absolute risk reduction, 2.5 percentage points; 95% CI, 1.5 to 3.5). The composite outcome of major and clinically relevant nonmajor bleeding occurred in 129 of 2673 patients assigned to apixaban (4.8%) and 134 of 2659 assigned to enoxaparin (5.0%) (absolute difference in risk, -0.2 percentage points; 95% CI, -1.4 to 1.0). CONCLUSIONS: Among patients undergoing hip replacement, thromboprophylaxis with apixaban, as compared with enoxaparin, was associated with lower rates of venous thromboembolism, without increased bleeding. (Funded by Bristol-Myers Squibb and Pfizer; ClinicalTrials.gov number, NCT00423319.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The WARFASA 309 and ASPIRE 318 trials compared aspirin, 100 mg daily, with placebo for secondary prevention of recurrent VTE for patients with an initial unprovoked event, and the pooled results of the 2 trials showed a decrease in recurrent VTE, as well as major vascular events, without an increased risk for clinically relevant bleeding. 309,315”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [318]
In the citing paper
“The investigation into the use of the lower doses of these 2 anticoagulants for secondary prevention was prompted by the desire to reduce the risk of bleeding, as well as the documented efficacy of the lower doses to prevent VTE after elective hip or knee arthroplasty. 317-321”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [318]
Citations
Cites
Prevention of Venous Thromboembolism
Geerts, W. H., Pineo, G. F., Heit, J. A., Bergqvist, D., Lassen, M. R., Colwell, C. W., & Ray, J. G. (2004) · Chest · doi:10.1378/chest.126.3_suppl.338s · Cited by 5,895
Self-citationSCHULMAN, S., & KEARON, C. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01204.x · Cited by 5,009
Prevention of Venous Thromboembolism
Geerts, W. H., Heit, J. A., Clagett, G. P., Pineo, G. F., Colwell, C. W., Anderson, F. A., & Wheeler, H. B. (2001) · Chest · doi:10.1378/chest.119.1_suppl.132s · Cited by 4,373
Self-citationPrevention of Venous Thromboembolism
Geerts, W. H., Bergqvist, D., Pineo, G. F., Heit, J. A., Samama, C. M., Lassen, M. R., & Colwell, C. W. (2008) · Chest · doi:10.1378/chest.08-0656 · Cited by 3,829
Self-citationSCHULMAN, S., ANGERÅS, U., BERGQVIST, D., ERIKSSON, B., LASSEN, M. R., & FISHER, W. (2010) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03678.x · Cited by 3,756
Self-citationDabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism
Schulman, S., Kearon, C., Kakkar, A. K., Mismetti, P., Schellong, S., Eriksson, H., Baanstra, D., Schnee, J., & Goldhaber, S. Z. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0906598 · Cited by 2,583
The Long-Term Clinical Course of Acute Deep Venous Thrombosis
Prandoni, P., Lensing, A. W. A., Cogo, A., Cuppini, S., Villalta, S., Carta, M., Cattelan, A. M., Polistena, P., Bernardi, E., & Prins, M. H. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-125-1-199607010-00001 · Cited by 2,109
Antithrombotic Therapy for Venous Thromboembolic Disease
Kearon, C., Kahn, S. R., Agnelli, G., Goldhaber, S., Raskob, G. E., & Comerota, A. J. (2008) · Chest · doi:10.1378/chest.08-0658 · Cited by 1,996
Self-citationRivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip Arthroplasty
Eriksson, B. I., Borris, L. C., Friedman, R. J., Haas, S., Huisman, M. V., Kakkar, A. K., Bandel, T. J., Beckmann, H., Muehlhofer, E., Misselwitz, F., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0800374 · Cited by 1,433
Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Total Knee Arthroplasty
Lassen, M. R., Ageno, W., Borris, L. C., Lieberman, J. R., Rosencher, N., Bandel, T. J., Misselwitz, F., & Turpie, A. G. G. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa076016 · Cited by 1,295
Self-citation
Cited by
Items 501–600 of 780
The New Era of Anticoagulation
Skeik, N., Rumery, K. K., & Rodriguez, G. T. (2013) · Annals of Vascular Surgery · doi:10.1016/j.avsg.2013.07.013 · Cited by 8
Haemostatic challenges in the cancer patient: Focus on the perioperative period
Burbury, K. (2013) · Best practice & research. Clinical anaesthesiology · doi:10.1016/j.bpa.2013.09.001 · Cited by 7
Using New Oral Anticoagulants in Patients Undergoing Major Orthopedic Surgery
Bass, A. R. (2015) · Current Rheumatology Reports · doi:10.1007/s11926-015-0498-z · Cited by 5
Pharmacological thromboprophylaxis and total hip or knee replacement
Frostick, S. P. (2016) · British Journal of Nursing · doi:10.12968/bjon.2016.25.1.45 · Cited by 6
Chen, J., Lv, M., Jiang, S., Wu, S., Xu, W., Qian, J., Zeng, Z., Chen, M., Fang, Z., & Zhang, J. (2022) · Vascular Medicine · doi:10.1177/1358863x221115213 · Cited by 5
Frederick, J. S., Weiner, T. R., Neuwirth, A. L., Shah, R. P., Geller, J. A., & Cooper, H. J. (2023) · Journal of Orthopaedic Experience & Innovation · doi:10.60118/001c.39784 · Cited by 5
Gómez-Cerezo, J. F., Arrayás, I. G., Súarez-Fernández, C., Nicolás, L. B., de Salas-Cansado, M., & Rubio‐Terres, C. (2012) · Revista Española de Cirugía Ortopédica y Traumatología · doi:10.1016/j.recot.2012.07.009 · Cited by 5
Apixaban for the prevention of stroke in atrial fibrillation
Littrell, R. L., & Flaker, G. C. (2012) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.11.187 · Cited by 5
Novel oral anticoagulants for the prevention of venous thromboembolism in surgical patients
Riva, N., Donadini, M. P., Bozzato, S., & Ageno, W. (2013) · Thrombosis Research · doi:10.1016/s0049-3848(13)70026-4 · Cited by 6
Rudakova, A. V. (2015) · Rational Pharmacotherapy in Cardiology · doi:10.20996/1819-6446-2015-11-3-287-292 · Cited by 5
Uso de los anticoagulantes orales directos en la práctica clínica
Salamanca, R. G. J., Gómez, J. D. J., & Roa, A. E. P. (2016) · Revista de la Facultad de Medicina · doi:10.15446/revfacmed.v64n2.49963 · Cited by 9
Venous thromboembolism controversies
Adum, J. P. S., Golemi, I., Rios, L. H. P., Quintero, L. A. D., Tafur, A. J., & Caprini, J. A. (2018) · Disease-a-Month · doi:10.1016/j.disamonth.2018.03.003 · Cited by 6
Фокин, А. А., & Bagaev, K. V. (2019) · Angiology and vascular surgery · doi:10.33529/angio2019102 · Cited by 7
Patriquin, C. J., & Crowther, M. A. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4557-2296-9.00026-9 · Cited by 7
Shapiro, J., Stillwagon, M. R., Padovano, A., Moll, S., & Lim, M. R. (2020) · The International Journal of Spine Surgery · doi:10.14444/7080 · Cited by 5
Shantsila, E., & Lip, G. Y. H. (2015) · Springer eBooks · doi:10.1007/978-3-319-25460-9_3 · Cited by 5
Newer Anticoagulants in Critically Ill Patients
Rajasekhar, A., Beyth, R. J., & Crowther, M. A. (2012) · Critical Care Clinics · doi:10.1016/j.ccc.2012.04.005 · Cited by 6
Nuevas perspectivas clínicas en el uso de los anticoagulantes orales directos
Marco, P., Zamorano, J. L., Chana, F., & Llau, J. V. (2013) · Medicina Clínica · doi:10.1016/j.medcli.2013.05.002 · Cited by 6
Swieton, J., Mikłosz, J., Yusa, S., Szczubiałka, K., Pawlak, D., Mogielnicki, A., & Kałaska, B. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222011149 · Cited by 4
Floyd, J. L., Porragas-Paseiro, H. S., Nguyen, C., Moroney, M. R., Mastroyannis, S. A., & Guntupalli, S. R. (2024) · Annals of Surgical Oncology · doi:10.1245/s10434-024-15369-8 · Cited by 4
“7–9 Importantly, an effective anticoagulant prevents venous thromboembolism without increasing the rate of bleeding events, another significant postoperative risk for gynecologic cancer patients.”
Venous Thromboembolism in Orthopaedic Surgery
Justin, R., & Michael, H. (2012) · InTech eBooks · doi:10.5772/31770 · Cited by 4
“It was found to be more efficacious than once-daily dosing of enoxaparin, but failed to demonstrate non-inferiority to twice daily dosing of enoxaparin (Lassen et al., 2009; Lassen et al 2010b).”
BackgroundThromboseprophylaxe in der muskuloskelettalen Chirurgie
Pabinger-Fasching, I., Eichinger-Hasenauer, S., Grohs, J. G., Hochreiter, J., Kastner, N., Korninger, H. C., Kozek‐Langenecker, S. A., Marlovits, S., Niessner, H., Rachbauer, F., et al. (2014) · Wiener klinische Wochenschrift · doi:10.1007/s00508-014-0509-5 · Cited by 5
“407 HTEP-Patienten verglichen [27].”
Liew, A., Eikelboom, J. W., & O'Donnell, M. J. (2013) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12440 · Cited by 4
Liem, T. K., & DeLoughery, T. G. (2011) · Seminars in Vascular Surgery · doi:10.1053/j.semvascsurg.2011.11.003 · Cited by 5
Venous Thromboembolism Prophylaxis in the Nursing Home: To Do or Not To Do?
Dharmarajan, T. S., & Norkus, E. P. (2013) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2013.05.001 · Cited by 4
Bon usage d’apixaban : que retenir pour la pratique
Albaladejo, P., Deplanque, D., Fossati, F., Mahagne, M., Mismetti, P., Nguyên, P., Roy, P., Touzé, E., & Mourad, J. (2014) · Journal des Maladies Vasculaires · doi:10.1016/j.jmv.2014.09.002 · Cited by 4
Meddahi, S., & Samama, M. M. (2014) · Journal des Maladies Vasculaires · doi:10.1016/j.jmv.2014.02.001 · Cited by 4
Fernández, C. S., Cerezo, J. F. G., Arrayás, I. G., Nicolás, L. B., de Salas-Cansado, M., & Rubio‐Terres, C. (2013) · PharmacoEconomics Spanish Research Articles · doi:10.1007/s40277-013-0015-6 · Cited by 4
Understanding the New Emerging Oral Anticoagulants for Venous Thromboembolism Prophylaxis
Welle, M. K. (2012) · Orthopaedic Nursing · doi:10.1097/nor.0b013e31826649a0 · Cited by 4
Clinico-Pharmacological and Clinical Basis of Multiplicity of Intake of Novel Oral Anticoagulants
Sychev, D. A., Sinitsina, I. I., Tsomaya, I. V., Vardanyan, A. V., & Леванов, А. Н. (2017) · Kardiologiia · doi:10.18087/cardio.2017.11.10058 · Cited by 4
Weinberg, I., & Jaff, M. R. (2013) · Springer eBooks · doi:10.1007/978-1-4471-4528-8_37 · Cited by 4
Novel Oral Anticoagulants for the Prevention and Treatment of Thromboembolism
Oliphant, C. S., Jacobs, A. R., Kabra, R., & Das, P. (2013) · Future Cardiology · doi:10.2217/fca.13.76 · Cited by 4
“54) [36]”
BackgroundStacy, Z. A. (2013) · Europe PMC (PubMed Central) · Cited by 8
Prophylaxis for Deep Vein Thrombosis and Pulmonary Embolism in the Surgical Patient
Galanis, T., Kraft, W. K., & Merli, G. J. (2011) · Advances in Surgery · doi:10.1016/j.yasu.2011.05.001 · Cited by 5
“7%) [56].”
New anticoagulants in the prevention and treatment of venous thromboembolism
Keltai, M., & Keltai, K. (2011) · Orvosi Hetilap · doi:10.1556/oh.2011.29140 · Cited by 5
Gómez-Cerezo, J. F., Arrayás, I. G., Súarez-Fernández, C., Nicolás, L. B., de Salas-Cansado, M., & Rubio‐Terres, C. (2012) · Revista Española de Cirugía Ortopédica y Traumatología · doi:10.1016/j.recote.2012.10.005 · Cited by 4
Neue orale direkte Antikoagulanzien: Viele Vorteile, aber offene Fragen
Haas, S. K., & Schellong, S. (2014) · Der Internist · doi:10.1007/s00108-013-3424-3 · Cited by 5
The safety and efficacy of apixaban: where do we stand in 2013?
Brito, F. D. S., Lópes, R. D., & Alexander, J. H. (2013) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2013.799663 · Cited by 4
“This dose of apixaban showed less bleeding than enoxaparin 30 mg twice daily and similar bleeding when compared with enoxaparin 40 mg once daily [17].”
BackgroundNew Anticoagulants for Thrombo-embolic Disease: Clinical Implications
Campbell, A. R., McKnight, R., & Dedhia, H. V. (2011) · Journal of Pharmacogenomics & Pharmacoproteomics · doi:10.4172/2153-0645.1000104 · Cited by 4
“Similarly, an early study with LY-517717 in patients undergoing hip arthroplasty or total knee surgery showed noninferiority at doses of 100mg to 150mg daily when compared to enoxaparin 40mg given subcutaneously daily.”
BackgroundInfluentialPerioperative Management of Oral Anticoagulants: A Focus on Target-Specific Oral Anticoagulants
Barnes, G. D., Eagle, K. A., & Froehlich, J. B. (2014) · Hospital Practice · doi:10.3810/hp.2014.08.1118 · Cited by 4
Rendering factor Xa zymogen-like as a therapeutic strategy to treat bleeding
Thalji, N. K., & Camire, R. M. (2017) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000369 · Cited by 4
Yan, K., Yan, P., Cao, L., Su, J., Zhang, Q., Zhang, L., & Jiang, X. (2025) · Neurosurgical Review · doi:10.1007/s10143-025-03409-0 · Cited by 3
“The use of LMWH and new oral anticoagulants increases the risk of bleeding events and heparin-induced thrombocytopenia (HIT) [3, 7].”
Nam, R. H. K., Selim, A. A. H. A., Gaddoura, Z., Choudhary, Z. A., Farhan-Alanie, M. M. H., Mohammed, H., Griffin, X. L., & Thomas, G. (2025) · The Journal of Arthroplasty · doi:10.1016/j.arth.2025.10.067 · Cited by 3
Prophylactic-Dose Rivaroxaban Transfer Into Human Milk
Bruno, A. M., Job, K. M., Rower, J. E., Allshouse, A. A., Zinkhan, E. K., Lim, M. Y., Shakib, J. H., Federspiel, J. J., Watt, K., Metz, T. D., et al. (2025) · Obstetrics and Gynecology · doi:10.1097/aog.0000000000006153 · Cited by 3
Ng, H. J., Chee, Y. L., Kuperan, P., Lim, L. C., Tan, D. C. L., Tay, J. C., Handa, P. K., Ali, M. A., & Lee, L. H. (2013) · Annals of the Academy of Medicine Singapore · doi:10.47102/annals-acadmedsg.v42n11p593 · Cited by 3
New anticoagulants: pharmacology and clinical studies
Samama, C. M. (2011) · Wiener Medizinische Wochenschrift · doi:10.1007/s10354-011-0875-9 · Cited by 3
“Eventually, the results of the European hip replacement study (ADVANCE-3) are even more interesting [9].”
BackgroundCramer, C. L., Cunningham, M. R., Zhang, A. M., Pambianchi, H. L., James, A. L., Lattimore, C. M., Cummins, K. C., Turkheimer, L. M., Turrentine, F. E., & Zaydfudim, V. M. (2024) · Journal of Gastrointestinal Surgery · doi:10.1016/j.gassur.2023.11.020 · Cited by 3
Ganta, S., Muralidhar, P., Gunupuru, S. K., Salakolusu, S., Bevara, S., Padhy, H., & Ganta, R. K. (2024) · Biomedical Chromatography · doi:10.1002/bmc.6027 · Cited by 4
Shantsila, E., & Lip, G. Y. H. (2015) · Springer eBooks · doi:10.1007/978-3-319-25460-9_2 · Cited by 3
Ying, Q., Hao, S.-N., Zhang, J., Chengbin, Z., & Lian, Y. (2017) · Biomedical Research-tokyo · Cited by 3
Interaction Between Direct Factor Xa Inhibitors and Digoxin
Sokol, J., Neháj, F., Ivanková, J., & Mokáň, M. (2018) · American Journal of Therapeutics · doi:10.1097/00045391-900000000-98563 · Cited by 3
Rainville, T., Laskine, M., & Durand, M. (2019) · BMJ Evidence-Based Medicine · doi:10.1136/bmjebm-2018-111057 · Cited by 3
Münzel, T. F., & Konstantinides, S. (2012) · Hämostaseologie · doi:10.5482/hamo-12-05-0010 · Cited by 3
“Auf der Basis der Ergebnisse von ADVANCE-2 und –3 wurde Apixaban im Mai 2011 für die Prophylaxe venöser Thromboembolien bei Erwachsenen nach elektivem Knie- oder Hüftgelenkersatz in Europa zugelassen.”
BackgroundInfluentialReal-world data confirm clinical trial outcomes for rivaroxaban in orthopaedic patients
Kwong, L. M., & Turpie, A. G. G. (2015) · Current Orthopaedic Practice · doi:10.1097/bco.0000000000000232 · Cited by 3
Lussana, F., Cattaneo, M., & Squizzato, A. (2015) · Thrombosis and Haemostasis · doi:10.1160/th15-01-0073 · Cited by 3
“The experimental drug was dabigatran in two studies (23, 24), apixaban in one (28), and rivaroxaban in two (18, 19).”
BackgroundXuan, D., McBride, S. J., Wastall, P., Porcari, A. R., DiCarlo, L. A., & Boyd, R. A. (2015) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.232 · Cited by 3
Stoberock, K., Debus, E. S., Larena-Avellaneda, A. A., & Kieback, A. G. (2013) · Gefässchirurgie · doi:10.1007/s00772-013-1186-9 · Cited by 3
Sarvananthan, T., & Das, S. (2012) · Phlebology The Journal of Venous Disease · doi:10.1258/phleb.2012.012s33 · Cited by 3
Pebanco, G. D. O., Kaiser, S., & Haines, S. T. (2013) · Annals of Pharmacotherapy · doi:10.1345/aph.1r247 · Cited by 5
Anticoagulation and Non-urgent Commercial Air Travel: A Review of the Literature
Nunnally, B., Josseaume, J., Duchateau, F. X., O’Connor, R. E., Verner, L., & Brady, W. J. (2015) · Air Medical Journal · doi:10.1016/j.amj.2015.06.006 · Cited by 3
Oral Factor Xa and Direct Thrombin Inhibitors: A Clinical Perspective
Thethi, I., Lewis, B., & Fareed, J. (2012) · Journal of Burn Care & Research · doi:10.1097/bcr.0b013e318248bc4c · Cited by 4
Primary prevention of venous thromboembolism
Figueiredo, R., Stansby, G. P., & Bhattacharya, V. (2012) · Phlebology The Journal of Venous Disease · doi:10.1258/phleb.2012.012s32 · Cited by 4
Recomendações da SBA para segurança na anestesia regional em uso de anticoagulantes
Fonseca, N. M., de Anestesiologia, S. B., Alves, R. R., & Pontes, J. P. J. (2013) · Brazilian Journal of Anesthesiology · doi:10.1016/j.bjan.2013.04.008 · Cited by 5
Outpatient Oral Anticoagulant Therapy
Ansell, J. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-46202-0.00037-6 · Cited by 4
Гуляихина, Д. Е. (2019) · HERALD of North-Western State Medical University named after I I Mechnikov · doi:10.17816/mechnikov201911179-92 · Cited by 4
Bouvenot, G., Bounhoure, J., Montastruc, J., & Vacheron, A. (2014) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/s0001-4079(19)31265-8 · Cited by 8
Pulmonary Embolism and Deep Vein Thrombosis
Goldhaber, S. Z., & Piazza, G. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4557-0101-8.00038-2 · Cited by 5
Ko, D., Kapoor, A., Rose, A. J., Hanchate, A. D., Miller, D. R., Winter, M. R., Palmisano, J. N., Henault, L. E., Fredman, L., Walkey, A. J., et al. (2020) · Vascular Medicine · doi:10.1177/1358863x20927096 · Cited by 3
Kunal, K., Banerjee, S., Garg, P. K., & Elhence, A. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14959 · Cited by 4
“6%), which is comparable to previously reported data of 2–4%.(11,13) The incidence of bleeding complication was found to be more in THA (82.”
ResultLucey, J. M., King, A. E., Hammond, D. A., & Nemecek, B. D. (2019) · ASHP eBooks · doi:10.37573/9781585285525.004 · Cited by 3
Kumar, M. A. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4377-0167-8.00015-7 · Cited by 3
Kumbhani, D. J., Armbruster, A. L., Cheng, R. K., Chrispin, J., Fischer, U., Holbrook, A. M., Joglar, J., & Sevestre, M.-A. (2026) · JACC · doi:10.1016/j.jacc.2026.05.033 · Cited by 2
Brodmann, M. (2013) · Hämostaseologie · doi:10.5482/hamo-13-02-0005 · Cited by 3
New drugs and their performance 10 years after approval: a systematic analysis
Manfouo, B., & Seifert, R. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-04178-9 · Cited by 5
Zheng, X., Wang, L., Chen, Y., Liu, L., Zhang, Z., & Xiao, C. (2025) · Frontiers in Surgery · doi:10.3389/fsurg.2025.1483611 · Cited by 2
Macklin, C. S., Reznik, G., Gleave, M. E., Mannas, M. P., Black, P. C., & St-Laurent, M.-P. (2025) · Canadian Urological Association Journal · doi:10.5489/cuaj.9312 · Cited by 2
Manivasagam, S. S., Aminsharifi, A., & Raman, J. D. (2026) · Journal of Personalized Medicine · doi:10.3390/jpm16020082 · Cited by 2
Timeless therapeutics: cardiac indications for vitamin K antagonists in clinical practice
Kempers, E. K., de Jong, M. J., Cate, H. T., Caterina, R. D., & Kruip, M. J. H. A. (2026) · Heart · doi:10.1136/heartjnl-2024-324551 · Cited by 2
Unmet Needs in Anticoagulant Therapy: Potential Role of Rivaroxaban
Eikelboom, J. W., & Connolly, S. J. (2015) · Cardiology Research · doi:10.14740/cr413w · Cited by 2
“Dabigatran, apixaban and rivaroxaban are approved for these indications based on comprehensive clinical trial programs that collectively randomized more than 34,000 patients [26-38].”
BackgroundFabbian, F., Giorgi, A. D., Tiseo, R., Zucchi, B., & Manfredini, R. (2016) · Patient Preference and Adherence · doi:10.2147/ppa.s82484 · Cited by 3
Evans, N. S. (2018) · Springer eBooks · doi:10.1007/978-3-319-73709-6_5 · Cited by 3
Felber, M., Rozet, F., Droupy, S., Misraï, V., Smadja, D. M., & Morgan Rouprêt, A. (2018) · The French Journal of Urology · doi:10.1016/j.purol.2018.09.002 · Cited by 2
Venous thromboembolism after total joint arthroplasty: Risk stratification and prophylaxis
Kang, H. P., & Lieberman, J. R. (2018) · Seminars in Arthroplasty JSES · doi:10.1053/j.sart.2019.01.004 · Cited by 2
Koo, K. (2019) · Clinical Orthopaedics and Related Research · doi:10.1097/corr.0000000000000749 · Cited by 2
“previous clinical trials [2-4, 13] and showed, in my opinion, that”
Panchal, H., Agashe, A., Sancheti, P. K., Kulkarni, N., & Taur, S. R. (2021) · SAGE Open Medicine · doi:10.1177/20503121211049962 · Cited by 2
Direct Oral Anticoagulants: Drug Selection by Means of the SOJA Method
Janknegt, R., Metting, E., Kooistra, J., & Dekhuijzen, R. P. N. (2020) · Acta Scientific Pharmaceutical Sciences · doi:10.31080/asps.2020.04.0640 · Cited by 2
Antiphospholipid Syndrome Novel Therapies
Bittar, M. N., & Uthman, I. W. (2014) · EMJ Rheumatology · doi:10.33590/emjrheumatol/10312311 · Cited by 2
Bagheri, A. B., Dehghani, M. J., & Aghajanian, S. (2024) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2024.108205 · Cited by 2
Bajpai, V., Patel, T. K., Dwivedi, P., Kabi, A., Mishra, A., Sharma, R. S., Gupta, A., Gangwar, P., Agarwal, R., & Kishore, S. (2025) · Cardiovascular & Hematological Agents in Medicinal Chemistry · doi:10.2174/0118715257331706240919172310 · Cited by 2
Ten-Year Trends in Venous Thromboembolism Prophylaxis at a High-Volume Arthroplasty Center
Lizcano, J. D., Sherman, M. B., Tarabichi, S., Baker, C. M., Reddy, Y., & Austin, M. S. (2024) · Journal of the American Academy of Orthopaedic Surgeons · doi:10.5435/jaaos-d-24-00507 · Cited by 2
Telang, S. S., Palmer, R. C., Dobitsch, A. A., Ball, J. R., Heckmann, N. D., & Lieberman, J. R. (2024) · Arthroplasty Today · doi:10.1016/j.artd.2024.101548 · Cited by 2
Influence des nouveaux anticoagulants sur les examens de la coagulation Intérêt en clinique
Samama, M. M., Flem, L. L., & Émile, C. (2013) · Archives des Maladies du Coeur et des Vaisseaux - Pratique · doi:10.1016/s1261-694x(13)70534-0 · Cited by 3
Galanis, T., & Merli, G. J. (2013) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-013-0955-3 · Cited by 2
“5 orally twice daily or enoxaparin 40 mg sc once daily for 35 days [16].”
BackgroundNutescu, E. A. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.774374 · Cited by 3
“001 for non-inferiority and superiority) [50].”
Rolle der neuen oralen Antikoagulanzien im Vergleich zu Vitamin-K-Antagonisten in der Praxis
Osterspey, A., & Krome, A. (2012) · Herz · doi:10.1007/s00059-012-3619-8 · Cited by 2
Schwabe, U., & Fricke, U. (2012) · Springer eBooks · doi:10.1007/978-3-642-29242-2_2 · Cited by 3
Insights into direct anticoagulants
Saad, E., & Dally, N. (2015) · Blood Coagulation & Fibrinolysis · doi:10.1097/mbc.0000000000000291 · Cited by 2
Charoin-Pannier, A., McIntyre, C., Zandt, H., Ciorciaro, C., Winters, K., Pepper, T., & Schmitt, C. (2012) · Thrombosis and Haemostasis · doi:10.1160/th12-01-0023 · Cited by 2
Anticoagulation with rivaroxaban: covering a broad spectrum of thromboembolic disease
Schellong, S. (2013) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.2013.811979 · Cited by 2
Novel Anticoagulant Use for Venous Thromboembolism: A 2013 Update
Perez, A. D., & Merli, G. J. (2013) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-013-0230-0 · Cited by 2
Metadata
- Authors
- Lassen, M. R., Gallus, A., Raskob, G. E., Pineo, G., Chen, D., & Ramirez, L. M.
- Affiliations
- University of Copenhagen (DK)
- South Australia Pathology (AU)
- University of Oklahoma Health Sciences Center (US)
- University of Calgary (CA)
- Bristol-Myers Squibb (United States) (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2010-12-23
- Volume
- 363
- Issue
- 26
- Pages
- 2487-2498
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2133686162
- Cited by
- 775
- References
- 35
- Citations by year
- 2026: 14 · 2025: 18 · 2024: 32 · 2023: 18 · 2022: 25 · 2021: 33 · 2020: 34 · 2019: 39 · 2018: 41 · 2017: 39 · 2016: 62 · 2015: 66 · 2014: 67 · 2013: 121 · 2012: 102
- FWCI
- 76.58
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Murdoch University Research Portal (submittedVersion)
- Flinders Academic Commons (Flinders University) (submittedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Topics
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Keywords
- apixaban, enoxaparin, thromboprophylaxis, total hip arthroplasty, factor Xa inhibitors, low molecular weight heparin, deep vein thrombosis, pulmonary embolism, bleeding risk, venography, non-inferiority, postoperative thromboprophylaxis, oral anticoagulants, venous thromboembolism
- MeSH terms
- Administration, Oral, Adult, Aged, Aged, 80 and over, Anticoagulants, Double-Blind Method, Female, Hemorrhage, Humans, Injections, Subcutaneous, Male, Middle Aged, Postoperative Complications, Pyrazoles, Pyridones, Confidence Intervals, Treatment Outcome, Enoxaparin, Arthroplasty, Replacement, Hip, Venous Thromboembolism, Young Adult, Factor Xa Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.